• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Emergency Classics

The NINDS trial: Tissue plasminogen activator in acute ischemic stroke significantly improves functional outcomes [Classics Series]

byAndrew Cheung, MD MBAandMarc Succi, MD
November 8, 2014
in Emergency Classics, General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Treatment of acute ischemic stroke with tissue plasminogen activator within 3 hours of symptom onset significantly improves functional outcomes three months after the incident, when compared with placebo 

2. Tissue plasminogen activator is significantly associated with higher rates of symptomatic intracerebral hemorrhage

Original Date of Publication: December 1995

Study Rundown: Prior to the NINDS trial, there had been some evidence that thrombolytic therapy benefitted patients with ischemic stroke, though intracerebral hemorrhage was a frequent complication. Several previous studies had found that early treatment (i.e., thrombolytics within 3 hours of symptom onset) was associated with the greatest likelihood of recovery and lower risks of hemorrhage. The NINDS trial was a larger randomized controlled trial that sought to assess the efficacy of using t-PA in treating ischemic stroke within 3 hours of symptom onset.

According to the results, the administration of tissue plasminogen activator (t-PA) within three hours of symptom onset in patients suffering ischemic stroke significantly improves functional outcomes, as observed at the three month mark. Patients treated with t-PA, however, suffered significantly higher rates of symptomatic bleeding.

The NINDS trial was the first randomized controlled trial demonstrating that t-PA was beneficial in patients suffering from acute ischemic stroke. While these benefits were shown in a very carefully selected sample of stroke cases, the findings of the NINDS trial were used as the basis for approving the use of thrombolytics in the management of acute strokes and informed the development of practice guidelines in centres across North America.

RELATED REPORTS

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

Mazdutide significantly reduces weight in adults with overweight or obesity

Click to read study in NEJM

In-Depth [randomized, controlled study]: The trial consisted of two phases: 1) the first phase involved assessing for improvements in neurologic functioning within 24 hours of symptom onset to measure t-PA activity, and 2) the second phase involved assessing for sustained clinical improvement at 3 months. In phase 1, there was no significant difference between the two groups in terms of neurologic improvement within the first 24 hours. In phase 2, patients treated with t-PA demonstrated significant improvements on several functional assessment scales (i.e., NIHSS, Barthel, Modified Rankin, Glasgow Outcome) three months after the onset of stroke, when compared with patients in the placebo group. There were significantly more symptomatic intracerebral hemorrhages in the t-PA group, though the rate of asymptomatic intracerebral hemorrhages was not different.

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Previous Post

Children of obese mothers have diminished cognitive abilities in mid-childhood

Next Post

[In the News] Extended tamoxifen regimen reduces mortality for subset of breast cancer

RelatedReports

Cardiology

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

July 11, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Pharma

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

July 11, 2025
Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

July 10, 2025
Next Post

[In the News] Extended tamoxifen regimen reduces mortality for subset of breast cancer

Novel antiviral drug reduces influenza viral load

Bronchial foreign bodies more common than tracheal foreign bodies in a pediatric population

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.